RBC Capital Reaffirms Their Hold Rating on Intercept Pharma (ICPT)

In a report issued on January 7, Brian Abrahams from RBC Capital maintained a Hold rating on Intercept Pharma (ICPTResearch Report), with a price target of $33.00. The company’s shares closed last Wednesday at $28.58, close to its 52-week low of $23.78.

According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 8.6% and a 47.9% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Intra-Cellular Therapies, and Karyopharm Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Intercept Pharma with a $56.67 average price target, implying a 93.5% upside from current levels. In a report issued on January 5, Merrill Lynch also maintained a Hold rating on the stock with a $40.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $114.99 and a one-year low of $23.78. Currently, Intercept Pharma has an average volume of 1.01M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.